Evidence map›Paper›PMID 31955360›Full record

ArticleAIDS and behavior2020

The Effect of Depression on Adherence to HIV Pre-exposure Prophylaxis Among High-Risk South African Women in HPTN 067/ADAPT.

Jennifer Velloza, Renee Heffron, K Rivet Amico, Ali Rowhani-Rahbar, James P Hughes, Maoji Li, Bonnie J Dye, Connie Celum, Linda-Gail Bekker, Robert M Grant and 1 more

Open access · greenAbstract read
In one paragraph

Article in AIDS and behavior, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 3 pooled it
0.3field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 3 syntheses or guidelines pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pre-exposure Prophylaxis Adherence Among Men Who Have Sex With Men: A Systematic Review and Meta-analysis.Journal of preventive medicine and public health = Yebang Uihakhoe chi · 2024
    Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Article
  9. Article
  10. Article
  11. Article
  12. High Retention and Adherence With Rapid Long-acting Injectable Preexposure Prophylaxis Implementation in an Urban Safety Net Clinic Population.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Jennifer VellozaDepartment of Epidemiology, University of Washington, Seattle, WA, USA. jvelloza@uw.edu.ORCID http://orcid.org/0000-0001-7242-7415
Renee HeffronDepartment of Epidemiology, University of Washington, Seattle, WA, USA.
K Rivet AmicoUniversity of Michigan, Ann Arbor, MI, USA.
Ali Rowhani-RahbarDepartment of Epidemiology, University of Washington, Seattle, WA, USA.
James P HughesFred Hutchinson Cancer Research Center, Seattle, WA, USA.
Maoji LiFred Hutchinson Cancer Research Center, Seattle, WA, USA.
Bonnie J Dye, FHI 360, Durham, NC, USA.
Connie CelumDepartment of Global Health, University of Washington, Seattle, WA, USA.
Linda-Gail BekkerThe Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa.
Robert M GrantUniversity of California at San Francisco, San Francisco, CA, USA.
HPTN 067/ADAPT Study Team
University of Washington · USDesmond Tutu HIV Foundation · ZAFamily Health International 360 · USGladstone Institutes · US

Funding

LOC: HIV Prevention Trials NetworkUM1AI068619 · NIAID · FAMILY HEALTH INTERNATIONAL · PI MYRON Scott COHEN, Sinead Delany-Moretlwe · 2011 to 2026
$779.5M
SDMC: HPTN 084 Pregnancy SupplementUM1AI068617 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Elizabeth Renata Brown, Deborah J Donnell · 2011 to 2026
$204.9M
LC: HIV Prevention Trials Network - Laboratory Support for the SARS-CoV-2 Seroprevalence Study (CoVPN 5002)UM1AI068613 · NIAID · JOHNS HOPKINS UNIVERSITY · PI SUSAN H ESHLEMAN, Mark A Marzinke · 2011 to 2026
$100.2M
Emory HIV/AIDS Clinical Trials UnitUM1AI069418 · NIAID · EMORY UNIVERSITY · PI Colleen F Kelley · 2012 to 2026
$46.0M
VENEREAL DISEASET32AI007140 · NIAID · UNIVERSITY OF WASHINGTON · PI Julia Cook Dombrowski · 1985 to 2026
$19.4M
Chemoprophylaxis and HIV Host InteractionsR01AI118575 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GRANT, ROBERT M. · 2015 to 2019
$2.9M
Depression and Pre-Exposure Prophylaxis Use among sub-Saharan African WomenF31MH113420 · NIMH · UNIVERSITY OF WASHINGTON · PI VELLOZA, JENNIFER · 2017 to 2018
$84k
National Institute of Allergy and Infectious Diseases UM1-AI068613National Institute of Allergy and Infectious Diseases UM1-AI068617National Institute of Allergy and Infectious Diseases UM1-AI068619National Institute of Allergy and Infectious Diseases UM1AI069418NIAID NIH HHS R01 AI118575NIAID NIH HHS T32 AI007140NIAID NIH HHS UM1 AI068613NIAID NIH HHS UM1 AI068617NIAID NIH HHS UM1 AI068619NIAID NIH HHS UM1 AI069418NIMH NIH HHS F31 MH113420
6 · The paper itself

Abstract

Oral pre-exposure prophylaxis (PrEP) is highly efficacious but low adherence undermines effectiveness. Depression, common in African women, may be a barrier to consistent PrEP use. We aimed to assess the relationship between depression, psychosocial mediators, and PrEP adherence among South African women. We analyzed data from 174 South African women in HPTN 067, an open-label oral PrEP trial conducted from 2011 to 2013. Participants were followed for 24 weeks. PrEP adherence was measured via Wisepill™ and weekly self-report interview data. We considered participants "adherent" at week 24 if Wisepill™ and interviews indicated that ≥ 80% of expected doses were taken in the prior month. Elevated depressive symptoms were assessed using the 20-item Center for Epidemiological Studies-Depression (CES-D) scale. We used marginal structural models to estimate the effect of elevated symptoms at baseline on PrEP adherence at week 24 and to assess whether the direct effect changed meaningfully after accounting for mediating effects of stigma, social support, and PrEP optimism. High PrEP adherence occurred less often among women with elevated depressive symptoms (N = 35; 44.3%) compared with those without (N = 52; 54.7%; adjusted relative risk [aRR]: 0.79; 95% confidence interval [CI] 0.63-0.99). The effect of elevated depressive symptoms on PrEP adherence persisted in models accounting for the mediating influence of stigma (aRR: 0.74; 95% CI 0.51-0.97) and PrEP optimism (aRR: 0.75; 95% CI 0.55-0.99). We also found a direct effect of similar magnitude and direction when accounting for social support as the mediating variable, although this adjusted relative risk estimate was not statistically significant (aRR: 0.77; 95% CI 0.57-1.03). Depressive symptoms were common and associated with lower PrEP adherence among South African women. Future work is needed to determine whether depression services integrated with PrEP delivery could improve PrEP effectiveness among African women.

Indexed as

AdultAnti-HIV AgentsBlack PeopleCohort StudiesDepressionDrug MonitoringFemaleHIV InfectionsHumansMedication AdherencePre-Exposure ProphylaxisProspective StudiesAnti-HIV AgentsAfricaDepressionHIVPre-exposure prophylaxisWomen

Identifiers

PMID31955360
PMCPMC7319871
OpenAlexW2999890328

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.